Clinical efficacy and safety of telmisartan 80 mg once daily compared with enalapril 20 mg once daily in patients with mild-to-moderate hypertension: Results of a multicentre study

International Journal of Clinical Practice, Supplement

Volumn , Issue 145, 2004, Pages 23-28

  Alcocer, Luis ^a,d   Fernandez Bonetti, P ^b   Campos, E ^a   Dominguez Henkel, R ^c   De La Fuente, J J ^c   Segovia Ayala, C ^c  

^a HOSPITAL GENERAL DE MÉXICO   (Mexico)

^b Cardiology Service   (Mexico)

^c Medical Department   (Mexico)

^d Circuito Fuentes de Pedregal   (Mexico)

Author keywords

Angiotensin II receptor blocker; Angiotensin converting enzyme inhibitor; Antihypertensives; Enalapril; Hypertension; Telmisartan

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; PLACEBO; TELMISARTAN;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD;

EID: 10344252254     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Salud SD. Informacion epidemiologica de morbilidad. Mexico: Direccion General de Epidemiologica, 1991.
2. Giles TD, Sander GE. Beyond the usual strategies for blood pressure reduction: therapeutic considerations and combination therapies. J Clin Hypertens 2001; 3: 346-53.
3. Yamamoto-Kimura L, Zamora-Gonzalez J, Garcia de la Torre G, et al. Prevalence of high blood pressure and associated coronary risk factors in an adult population of Mexico City. Arch Med Res 1998; 29: 341-9.
4. Aguilar-Salinas CA, Vazquez-Chavez C, Gamboa-Marrufo R, et al. Obesity, diabetes, hypertension, and tobacco consumption in an urban adult Mexican population. Arch Med Res 2001; 32: 446-53.
5. Guerrero-Romero F, Rodriguez-Moran M, Sandoval-Herrrera F, et al. Prevalence of hypertension in indigenous inhabitants of traditional communities from the north of Mexico. J Hum Hypertens 2000; 14: 555-9.
6. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002; 89 (Suppl. 2A): 3A-10A.
7. Nelson EB, Pool JL, Taylor AA. Pharmacology of angiotensin converting enzyme inhibitors. A review. Am J Med 1986; 81 (Suppl. 4C): 13-8.
8. Alcocer L, Campos C, Bahena JH, et al. Clinical acceptability of ACE inhibitor therapy in mild to moderate hypertension, a comparison between perindopril and enalapril. Cardiovasc Drugs Ther 1995; 9: 431-6.
9. Dzielak DJ. Comparative pharmacology of the angiotensin II receptor antagonists. Expert Opin Invest Drugs 1998; 7: 741-51.
10. 1 receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol 1993; 347 (Suppl.): R98.
11. Townsend R, Haggert B, Liss C, et al. Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension. Clin Ther 1995; 17: 911-23.
12. Gradman AH, Arcuri KE, Goldberg AI, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995; 25: 1345-50.
13. Burnier M, Maillard M. The comparative pharmacology of angiotensin II receptor antagonists. Blood Press 2001; 10 (Suppl. 1): 6-11.
14. Laeis P, Puchler K, Kirch W. The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J Hypertension 2001; 19 (Suppl. 1): S21-S32.
15. 1 receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv Ther 1998; 15: 206-17.
16. Wienen W, Entzeroth M, van Meel JCA, et al. A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist. Cardiovasc Drug Rev 2000; 18: 127-56.
17. Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs 2001; 61: 1501-29.
18. Neutel J, Smith DH. Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: meta-analysis of a clinical database. J Clin Hypertens 2003; 5: 58-63.
19. Levine B. Effect of eprosartan and enalapril in the treatment of black hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Curr Med Res Opin 1999; 15: 25-32.
20. Smith DHG, Neutel JM, Morgenstern P. Once-daily telmisartan compared with enalapril in the treatment of hypertension. Adv Ther 1998; 15: 229-40.
21. 1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. J Hypertens 1999; 17: 293-302.
22. Amerena J, Pappas S, Ouellet J-P, et al. ABPM comparison of the anti-hypertensive profiles of telmisartan and enalapril in patients with mild-to-moderate essential hypertension. J Int Med Res 2002; 30: 543-52.
23. Meredith PA, Donnelly R, Elliott HL, et al. Prediction of the antihypertensive response to enalapril. J Hyperten 1990; 8: 1085-90.
24. Mondal BK, Strouthidis TM, Cameron A, et al. Enalapril in the long-term treatment of elderly hypertensives. Nephron 1990; 55 (Suppl. 1): 96-7.
25. Espinel CH, Williams JL, Coughlin SS. Enalapril and lisinopril in the treatment of mild to moderate essential hypertension. Clin Ther 1990; 12: 181-90.
26. el Mangoush M, Singh NK, Kumar S, et al. Efficacy of enalapril in essential hypertension and its comparison with atenolol. Postgrad Med J 1990; 66: 446-9.
27. Maclean D, Ramsay LE, Richardson PJ. Enalapril and nifedipine in the treatment of mild to moderate essential hypertension: a 6 month comparison. Br J Clin Pharmacol 1990; 30: 203-11.
28. Weir MR, Haynie R, Vertes V, et al. A comparison of the efficacy and tolerability of enalapril and sustained-release diltiazem in mild to moderate essential hypertension. Clin Ther 1990; 12: 473-81.
29. Coulter DM, Edwards IR. Cough associated with captopril and enalapril. Br Med J (Clin Res Ed) 1987; 294: 1521-3.
30. Lindgren BR, Andersson RG. Angiotensin-converting enzyme inhibitors and their influence on inflammation, bronchial reactivity and cough. A research review. Med Toxicol Adverse Drug Exp 1989; 4: 369-80.
31. Just PM. The positive association of cough with angiotensin-converting enzyme inhibitors. Pharmacotherapy 1989; 9: 82-7.
32. Karlberg BE. Cough and inhibition of the renin-angiotensin system. J Hypertens 1993; 11 (Suppl. 3): S49-S52.
33. Jackson EA. Issues with antihypertensive therapy: safety perspectives. Drug Intell Clin Pharm 1988; 22: 115-24.
34. Oliverio MI, Coffman TM. Angiotensin-II receptors: new targets for antihypertensive therapy. Clin Cardiol 1997; 20: 3-6.
35. Neutel JM, Smith DHG, Reilly PA. The efficacy and safety of telmisartan compared to enalapril in patients with severe hypertension. Int J Clin Pract 1999; 53: 175-8.
36. Lacourcière Y, the Telmisartan Cough Study Group. The incidence of cough: a comparison of lisinopril, placebo and telmisartan, a novel angiotensin II antagonist. Int J Clin Pract 1999; 53: 99-103.